A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 12 Sep 2015

At a glance

  • Drugs Maraviroc (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms MOTIVATE-2
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Sep 2015 Pooled analysis (SINGLE + MOTIVATE); Missing CD4+ cell response, results published in the HIV Clinical Trials.
    • 27 Jul 2012 Results from a pooled analysis of MOTIVATE-1 and -2 presented at the 19th International AIDS Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top